| Autor: |
Wolfe, Daniel N, Arangies, Elizabeth, David, Gloria L, Armstrong, Brian, Scocca, Theresa Z, Fedler, Janel, Natarajan, Ramya, Zhou, James, Jayashankar, Lakshmi, Donis, Ruben, Nesin, Mirjana, Meissner, H Cody, Lemiale, Laurence, Kovacs, Gerald R, Rele, Shyam, Mason, Robin, Cao, Huyen |
| Předmět: |
|
| Zdroj: |
Clinical Infectious Diseases; 10/15/2024, Vol. 79 Issue 4, p928-935, 8p |
| Abstrakt: |
In response to the coronavirus disease 2019 (COVID-19) pandemic, vaccines were quickly and successfully developed and deployed, saving millions of lives globally. While first-generation vaccines are safe and effective in preventing disease caused by SARS-CoV-2, next-generation vaccines have the potential to improve efficacy and safety. Vaccines delivered by a mucosal route may elicit greater protective immunity at respiratory surfaces, thereby reducing transmission. Inclusion of viral antigens in addition to the spike protein may enhance protection against emerging variants of concern. Next-generation vaccine platforms with a new mechanism of action may necessitate efficacy trials to fulfill regulatory requirements. The Biomedical Advanced Research and Development Authority (BARDA) will be supporting Phase 2b clinical trials of candidate next-generation vaccines. The primary endpoint will be improved efficacy in terms of symptomatic disease relative to a currently approved COVID-19 vaccine. In this paper, we discuss the planned endpoints and potential challenges to this complex program. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
